Latest News
Five-Year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of SMA Achieved or Maintained the Ability to Sit, Stand or Walk
Summary of Data Presented After 5 years of treatment, 91% of children were alive – without treatment, children with Type 1 SMA would not be expected to live past 2 […]
Spinal Muscular Atrophy (SMA) Update in Best Practices: Recommendations for Diagnosis Considerations
Cure SMA is pleased to announce the publication of the first in a series of new resources to support the care of individuals living with Spinal Muscular Atrophy (SMA). As […]
Novartis Gene Therapies Releases Spring SMA Community Letter
Novartis Gene Therapies recently released an update to the SMA community related to clinical trials and long term follow up studies of Zolgensma, in addition to recent publications. Read the […]
What is Spinal Muscular Atrophy
Table of Contents What is SMA How Common is SMA Types of SMA Causes of SMA Carrier Testing Symptoms of SMA Diagnosis SMA Newborn Screening Treatment for SMA Outlook / […]
Cure SMA Attends Spring 2024 Professional Organization Conferences to Promote Findings from Industry Collaboration Initiatives
Cure SMA is pleased to announce the participation of scientific leadership in the 2024 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference (March 3 – 6, 2024) and the […]
SMA Community Advocacy Results in Key Accessible Air Travel Win
On May 16, after more than 2-years of advocacy and education by the SMA and disability communities, Cure SMA-supported legislation was signed into law making air travel safer and more […]